SCHEMBL31516663

SCHEMBL31516663

COc1ccc(C(C)(C)C)cc1S(=O)(=O)NC(=O)c1ccc(Cn2cccn2)c(Br)c1

nearest known ligand 0.45

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ KAT7 O95251 13/20 0.45
▸ KAT6A Q92794 13/20 0.45
▸ KAT6B Q8WYB5 8/20 0.45
▸ KAT5 Q92993 6/20 0.45
▸ KAT8 Q9H7Z6 6/20 0.45
▸ HDAC1 Q13547 1/20 0.41
▸ HDAC6 Q9UBN7 1/20 0.41
▸ ALPL P05186 1/20 0.41
▸ LMNA P02545 1/20 0.40
▸ TP53 P04637 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ WDR5 P61964 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31691246 0.92 ALPL (0.43) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31691394 0.91 KAT7 (0.44) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31516641 0.91 KAT7 (0.46) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31691386 0.90 ALPL (0.41) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31516707 0.90 KAT7 (0.48) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31691431 0.89 KAT7 (0.45) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31516723 0.89 KAT7 (0.44) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31691347 0.88 KAT7 (0.40) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31172569 0.88 KAT7 (0.42) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31525826 0.88 HDAC1 (0.54) KAT7KAT6AKAT6BKAT5KAT8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 — — US disclosed
US-20250304535-A1 KAT6 Inhibitors BEIGENE SWITZERLAND GMBH (CH) 2025-10-02 — — US disclosed
US-12428379-B2 Acylsulfonamide KAT6A inhibitors OLEMA PHARMACEUTICALS, INC. (US) 2025-09-30 — — US disclosed
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. 2025-05-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B KAT7 5/4885KAT6A 1/4885KAT6B 3/4885
US-20250304535-A1 KAT6 Inhibitors KAT6A, KAT6B, KAT2A KAT7 4/4885KAT6A 1/4885KAT6B 2/4885
US-12428379-B2 Acylsulfonamide KAT6A inhibitors KAT6A, KAT2A, KAT6B KAT7 5/4885KAT6A 1/4885KAT6B 3/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B KAT7 4/4885KAT6A 1/4885KAT6B 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback